A laboratory specialized in women's health


Lumír Ondřej Hanuš, a great name in cannabis research opens a laboratory dedicated to women's health

The Czech chemist and former partner of Raphael Mechoulam, Lumír Ondřej Hanuš, opens a laboratory in Israel following the Asana group's funding. In addition, this laboratory specializing in women's health will have for first mission to find a treatment for endometriosis.

Asana Bio Group in collaboration with Dr. Lumír Hanus

Asana Group is an Israeli firm that conducts research on cannabinoids and the development of treatments in the field of women's health. according to The Times of Israël, the company has invested 2,3 million dollars in a laboratory that will provide clinical trials in a range of medical products, based on cannabis. The project initiative is led by Czech Professor Lumír Ondřej Hanuš.

The laboratory of Lumír

Lumír is currently a chemist in the cannabis field, and formerly a collaborator of Professor Raphael Mechoulam. Lumír Ondřej Hanuš took part in the same research as the professor Mechoulam; they have identified all the active ingredients in cannabis. That is, more 140 cannabinoids and more 1000 active substances. In addition to 1992, Hanuš and William Anthony Devane have isolated and described for the first time the structure of anandamide, a cannabinoid neurotransmitter that originates from the human body.
Professor Lumír Ondřej Hanuš, and Yotam Hod, the CEO of Lumir Lab.
Lumir's laboratory is located at the Ein Kerem Biotechnology Park at the Hebrew University of Jerusalem. Its creation is the result of 2,3 millions of dollars financing from the Israeli company Asana. The latter specializes in treatments dedicated to women's health. By the way, the lab has already started working with Gynica. It is another research and development company, headed by Professor Moshe Hod, Yotam Hod's father.
Lumir Lab, an Israeli lab for the clinical validation of cannabis research.

According to, Yotam Hod the creation of this laboratory:

"Is a milestone for the cannabis industry in Israel and abroad" To date, the vast majority of cannabis products available in different markets have no scientific basis, which prevents the medical community to support the legitimacy of cannabis-based therapies. Our goal is to provide tools and solutions that do not exist on the market today and to establish an international quality standard in the medical cannabis market. "

Asana Bio Group intends to export the intellectual property for the production and marketing on the European market of new treatments and products dedicated to women's health.

Read also
"wonder woman" from US Cannabis


Endometriosis is a disease caused by the presence of endometrial cells outside the uterus. Gynecological pain is the most explicit symptom of endometriosis. This is a chronic condition that affects 5 to 20% of women of childbearing age. And 40% of these women complain of lower abdominal pain. It can be asymptomatic and does not require management ... But it can also cause punctual or chronic gynecological pain, and lead to infertility.

The disease affects more than 180 million women worldwide, the statement said.

In their first joint study, Hanush and Moshe Hod will study the use of cannabinoids to treat endometriosis, the disease affects the immune system, and cannabis seems to stop its spread. The first mission of the laboratory funded by Asana, will therefore be to find a cure for the disease.

The news of medical cannabis in applied biotechnology

Tags : biotechnologyIsraelMedicineNews